Loading
CUL4A (Cullin-4A) is a gene. The public catalogues list it as a drug target and a DNA repair gene, and an approved or late-stage drug is recorded against it. Tied to Multiple myeloma, Non-Hodgkin lymphoma, Myelodysplastic syndromes / neoplasms and 2 more.
Core component of multiple cullin-RING-based E3 ubiquitin-protein ligase complexes which mediate the ubiquitination of target proteins. As a scaffold protein may contribute to catalysis through positioning of the substrate and the ubiquitin-conjugating enzyme. The E3 ubiquitin-protein ligase activity of the complex is dependent on the neddylation of the cullin subunit and is inhibited by the association of the deneddylated cullin subunit with TIP120A/CAND1.
Open Targets scores its association with cancer at 0.63 (direct and indirect evidence; datatypes literature 0.98, genetic association 0.00, clinical 0.99).
In plain words · CUL4A (Cullin-4A) is a gene. The public catalogues list it as a drug target and a DNA repair gene, and an approved or late-stage drug is recorded against it. Tied to Multiple myeloma, Non-Hodgkin lymphoma, Myelodysplastic syndromes / neoplasms and 2 more.
CUL4A (Cullin-4A) is a gene. The public catalogues list it as a drug target and a DNA repair gene, and an approved or late-stage drug is recorded against it. Tied to Multiple myeloma, Non-Hodgkin lymphoma, Myelodysplastic syndromes / neoplasms and 2 more.
Core component of multiple cullin-RING-based E3 ubiquitin-protein ligase complexes which mediate the ubiquitination of target proteins.
No product in this corpus aims at CUL4A yet. Drugs bind the molecule precisely: to switch it off, flag the cell for the immune system, or deliver a payload.
Specificity not established: no corpus medicine is aimed at it and the catalogues give it only the roles drug-target, dna-repair; HPA finds the RNA tissue enhanced, which says where the protein sits but not whether the tumour differs from normal tissue. HPA CUL4A: RNA tissue enhanced (skeletal muscle 161 nTPM); no normal tissue stained high. Distribution: 3 cancer families in the corpus carry a prevalence row, label threshold or catalogue link for it (Multiple myeloma, Lymphoma, Myeloid neoplasms); Open Targets associates it with 4 specific cancer types at or above 0.5 (plasma cell myeloma, follicular lymphoma, myelodysplastic syndrome, mantle cell lymphoma). (No rule of scripts/fetch-target-specificity.ts fired.)
Sources: Human Protein Atlas CUL4A tissue; Open Targets ENSG00000139842 associations
First described 1996. Earliest sequence paper UniProt cites for the protein: Kipreos E.T. et al, Cell, 1996, "cul-1 is required for cell cycle exit in C. elegans and identifies a novel gene family". Source.
Sources: HGNC HGNC:2554 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt Q13619 (protein name, function text, keywords and locations (REST API)); Open Targets ENSG00000139842 (association with cancer (MONDO_0004992) 0.63; per-cancer scores at or above 0.5: plasma cell myeloma 0.61, non-Hodgkin lymphoma 0.59, myelodysplastic syndrome 0.56, follicular lymphoma 0.57, mantle cell lymphoma 0.55 (GraphQL API, CC0))
Core component of multiple cullin-RING-based E3 ubiquitin-protein ligase complexes which mediate the ubiquitination of target proteins. As a scaffold protein may contribute to catalysis through positioning of the substrate and the ubiquitin-conjugating enzyme. The E3 ubiquitin-protein ligase activity of the complex is dependent on the neddylation of the cullin subunit and is inhibited by the association of the deneddylated cullin subunit with TIP120A/CAND1. The functional specificity of the E3 ubiquitin-protein ligase complex depends on the variable substrate recognition component. DCX(DET1-COP1) directs ubiquitination of JUN. DCX(DDB2) directs ubiquitination of XPC. Locus 13q34 (HGNC).
RNA: tissue enhanced (skeletal muscle 161 nTPM), detected in all normal tissues.
No normal tissue stained high.
No cancer sample stained medium or high.
Human Protein Atlas version 25.1, antibody staining at reliability approved, enhanced or supported; used under CC BY-SA 3.0. Staining counts are patients per level in the atlas cohort, not population prevalence.
Query for this target: (TITLE:"CUL4A" OR ABSTRACT:"CUL4A" OR TITLE:"cullin 4A" OR ABSTRACT:"cullin 4A" OR TITLE:"Cullin-4A" OR ABSTRACT:"Cullin-4A") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about CUL4A, not a curated reading list.
Shares Myelodysplastic syndromes / neoplasms (MDS), Mantle cell lymphoma, Follicular lymphoma, Multiple myeloma.
Shares Myelodysplastic syndromes / neoplasms (MDS), Mantle cell lymphoma, Follicular lymphoma, Multiple myeloma.
Shares Myelodysplastic syndromes / neoplasms (MDS), Open Targets Platform.
Shares Myelodysplastic syndromes / neoplasms (MDS), Open Targets Platform.
Shares Myelodysplastic syndromes / neoplasms (MDS), Open Targets Platform.
Shares Myelodysplastic syndromes / neoplasms (MDS), Open Targets Platform.
Shares Myelodysplastic syndromes / neoplasms (MDS), Open Targets Platform.
Shares Myelodysplastic syndromes / neoplasms (MDS), Open Targets Platform.